These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32855282)

  • 1. Inducible deletion of CDK4 and CDK6 - deciphering CDK4/6 inhibitor effects in the hematopoietic system.
    Maurer B; Brandstoetter T; Kollmann S; Sexl V; Prchal-Murphy M
    Haematologica; 2021 Oct; 106(10):2624-2632. PubMed ID: 32855282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.
    Rodríguez-Díez E; Quereda V; Bellutti F; Prchal-Murphy M; Partida D; Eguren M; Kollmann K; Gómez de Cedrón M; Dubus P; Cañamero M; Martínez D; Sexl V; Malumbres M
    Blood; 2014 Oct; 124(15):2380-90. PubMed ID: 25157181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
    Dai M; Boudreault J; Wang N; Poulet S; Daliah G; Yan G; Moamer A; Burgos SA; Sabri S; Ali S; Lebrun JJ
    Cancer Res; 2021 Mar; 81(5):1332-1346. PubMed ID: 33372040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6.
    Malumbres M; Sotillo R; Santamaría D; Galán J; Cerezo A; Ortega S; Dubus P; Barbacid M
    Cell; 2004 Aug; 118(4):493-504. PubMed ID: 15315761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoiesis specific loss of Cdk2 and Cdk4 results in increased erythrocyte size and delayed platelet recovery following stress.
    Jayapal SR; Wang CQ; Bisteau X; Caldez MJ; Lim S; Tergaonkar V; Osato M; Kaldis P
    Haematologica; 2015 Apr; 100(4):431-8. PubMed ID: 25616574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear factor of activated T cells c1 mediates p21-activated kinase 1 activation in the modulation of chemokine-induced human aortic smooth muscle cell F-actin stress fiber formation, migration, and proliferation and injury-induced vascular wall remodeling.
    Kundumani-Sridharan V; Singh NK; Kumar S; Gadepalli R; Rao GN
    J Biol Chem; 2013 Jul; 288(30):22150-62. PubMed ID: 23737530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ablation of cdk4 and cdk6 affects proliferation of basal progenitor cells in the developing dorsal and ventral forebrain.
    Grison A; Gaiser C; Bieder A; Baranek C; Atanasoski S
    Dev Neurobiol; 2018 Jul; 78(7):660-670. PubMed ID: 29570951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.
    Scheicher R; Hoelbl-Kovacic A; Bellutti F; Tigan AS; Prchal-Murphy M; Heller G; Schneckenleithner C; Salazar-Roa M; Zöchbauer-Müller S; Zuber J; Malumbres M; Kollmann K; Sexl V
    Blood; 2015 Jan; 125(1):90-101. PubMed ID: 25342715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
    Yang C; Li Z; Bhatt T; Dickler M; Giri D; Scaltriti M; Baselga J; Rosen N; Chandarlapaty S
    Oncogene; 2017 Apr; 36(16):2255-2264. PubMed ID: 27748766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.
    Zhang Z; Golomb L; Meyerson M
    Cancer Res; 2022 Jun; 82(11):2171-2184. PubMed ID: 35395071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway.
    Fan H; Liu W; Zeng Y; Zhou Y; Gao M; Yang L; Liu H; Shi Y; Li L; Ma J; Ruan J; Cao R; Jin X; Chen J; Cheng G; Yang H
    Commun Biol; 2023 Oct; 6(1):1041. PubMed ID: 37833461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
    Jia Y; Domenico J; Swasey C; Wang M; Gelfand EW; Lucas JJ
    PLoS One; 2014; 9(5):e97448. PubMed ID: 24848372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
    Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
    Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CDK6 in cancer.
    Nebenfuehr S; Kollmann K; Sexl V
    Int J Cancer; 2020 Dec; 147(11):2988-2995. PubMed ID: 32406095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
    Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
    Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lineage specific composition of cyclin D-CDK4/CDK6-p27 complexes reveals distinct functions of CDK4, CDK6 and individual D-type cyclins in differentiating cells of embryonic origin.
    Bryja V; Pacherník J; Vondráček J; Souček K; Čajánek L; Horvath V; Holubcová Z; Dvořák P; Hampl A
    Cell Prolif; 2008 Dec; 41(6):875-893. PubMed ID: 19040567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganoderiol F purified from
    Li X; Xie Y; Peng J; Hu H; Wu Q; Yang BB
    Cell Cycle; 2019 Nov; 18(21):3030-3043. PubMed ID: 31544588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
    Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
    Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.